News Digest / Lukas Schmidt

Author: Lukas Schmidt

06:29am, Tuesday, Jun 02, 2026
Abivax stock plunged after Phase 3 trial results showed promising efficacy for obefazimod but revealed unexpected cancer cases at higher doses, stirring investor caution despite reassurances.